Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8156637 | 0.88 | HSP90AA1 (0.40) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| Hydrochloric Acid SCHEMBL8148674 | 0.87 | HSP90AA1 (0.40) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL6981310 | 0.86 | HSP90AA1 (0.42) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL1508003 | 0.82 | CYP19A1 (0.50) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3498547 | 0.81 | HDAC8 (0.39) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8149819 | 0.79 | HSP90AA1 (0.38) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL4978567 | 0.78 | HSP90AA1 (0.41) | HSP90AA1HSP90B1CYP11B1CYP11B2FNTA | |
| SCHEMBL30610947 | 0.77 | CYP11B1 (0.48) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL1507873 | 0.77 | CYP11B1 (0.48) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8149037 | 0.77 | HSP90AA1 (0.41) | HSP90AA1HSP90B1CYP11B1CYP11B2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | HSP90AA1 1462/4885HSP90B1 549/4885CYP11B1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.